Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Naproxen/pregabalin conjugate - Xgene Pharmaceutical

Next Previous
Drug Profile

Naproxen/pregabalin conjugate - Xgene Pharmaceutical

Alternative Names: XG 005; XG004 03; XG005 01; XG005 02; XG005 03

Latest Information Update: 28 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Xgene Pharmaceutical
  • Class Aminobutyric acids; Analgesics; Antiepileptic drugs; Antipyretics; Antirheumatics; Anxiolytics; Drug conjugates; Gabapentinoids; Naphthaleneacetic acids; Neuroprotectants; Nonsteroidal anti-inflammatories; Small molecules
  • Mechanism of Action CACNA2D1 protein modulators; Cyclooxygenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II/III Postoperative pain
  • Phase II Acute pain
  • Phase I/II Back pain; Neuropathic pain
  • Phase I Pain
  • No development reported Diabetic neuropathies

Most Recent Events

  • 28 Nov 2023 No recent reports of development identified for phase-I development in Diabetic-neuropathies in China (Topical, Gel)
  • 28 Nov 2023 No recent reports of development identified for phase-I development in Pain in China (Topical, Gel)
  • 10 Nov 2023 Efficacy, adverse event and pharmacokinetics data from a phase I trial in Pain presented at the ACR Convergence 2023 (ACR-2023)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top